Merkel Cell Carcinoma Market Size & Share, Market Trends, Epidemiology & Competitive Analysis Report 2032 | Companies – Bristol-Myers Squibb, Incyte Corporation

Merkel Cell Carcinoma Market
DelveInsight’s “Merkel Cell Carcinoma Market Insights, Epidemiology and Market Forecast 2032” report delivers an in-depth understanding of the Merkel Cell Carcinoma, historical and forecasted epidemiology as well as the Merkel Cell Carcinoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Merkel Cell Carcinoma (MCC) is a rare, highly aggressive neuroendocrine cutaneous neoplasm with a variable clinical presentation. It is a predominantly dermal-based lesion composed of monotonous small round cells with scanty cytoplasm, often difficult to differentiate from small round cell tumors, metastatic small cell carcinoma, blastic hematologic malignancies, and melanoma.

It is caused by ultraviolet (UV) light exposure, infection with HIV virus, autoimmune diseases (rheumatoid arthritis), and certain malignancies like chronic lymphocytic leukemia or lymphomas, which can profoundly suppress the immune system and may act as a causative agent in MCC. It is also associated with Merkel cell polyomavirus in more than 80% of cases.

DelveInsight’s “Merkel Cell Carcinoma Market Report 2032” report delivers an in-depth understanding of the Merkel Cell Carcinoma, historical and forecasted epidemiology as well as the Merkel Cell Carcinoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Geography Covered:

The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) & Japan

Merkel Cell Carcinoma Disease Understanding and Treatment Algorithm

In most people, the first sign of Merkel cell carcinoma is a small bump (nodule) on the skin. This bump is usually firm and appears either skin-coloured or red-purple. It also tends to grow rapidly. Often, there are no symptoms associated with the nodule.

Based on the American Joint Committee, MCC is divided into 4 stages, stage I tumor size of ≤2 cm, and stage II >2 cm, stage III as regional nodal disease, and stage IV as metastatic disease.

Request for sample pages:

“The incidence of MCC is generally higher in men than in women.”

Surgery is the primary treatment option for patients with loco-regional primary MCC. At all stages of MCC, physicians recommend complete excision of the primary tumor, verified by pathologic examination, after excision, if the risk of recurrence to the local lymph nodes is high, it is recommended that the lesion should be treated with a course of radiation therapy. This may destroy any cancer cells that are not detectable by physical exam and can help prevent recurrence of the disease. MCC is generally considered to be a chemotherapy-sensitive tumor, but responses are seldom durable.

Chemotherapy is reserved for the treatment of metastatic MCC (stage IV), and there is a growing opinion that it is mostly indicated to palliate symptoms. Commonly used regimens include. Adjuvant radiation therapy was associated with better outcomes compared with adjuvant chemotherapy.

The choice of treatment depends on the location of the tumor and comorbidities, highlighting the acute unmet need for effective treatment options with good safety and tolerability profile.

View full report @

Merkel Cell Carcinoma Therapy Assessment

1. Nivolumab by Bristol-Myers Squibb

2. INCMGA00012 by Incyte corporation

3. KRT 232 by Kartos Therapeutics

4. haNk and aNK cell therapies by NantKwest

Click here and get access to free sample pages of the Merkel Cell Carcinoma Market Report.

Table of contents

1 Key Insight

2 Executive Summary of Merkel Cell Carcinoma (MCC)

3 Merkel Cell Carcinoma (MCC) Market Overview at a Glance

4 Disease Background and Overview: Merkel Cell Carcinoma (MCC)

5 Case Reports

6 Merkel Cell Carcinoma (MCC) Epidemiology and Patient Population

7 United States Epidemiology

8 EU5 Epidemiology

9 Japan Epidemiology

10 Current Merkel Cell Carcinoma (MCC) Treatment and Medical Practices

11 Unmet needs

12 Merkel Cell Carcinoma (MCC) Marketed Drugs

13 Merkel Cell Carcinoma (MCC) Emerging Drugs

14 Merkel Cell Carcinoma (MCC) 7MM Market Analysis

15 United States

16 EU-5 countries: Market Outlook

17 Japan Market Outlook

18 Merkel Cell Carcinoma (MCC) Market Drivers

19 Merkel Cell Carcinoma (MCC) Market Barriers

20 SWOT Analysis

21 Reimbursement and market access

22 Appendix

23 DelveInsight Capabilities

24 Disclaimer

25 About DelveInsight

Related reports:

•      Merkel Cell Carcinoma Pipeline Insight, 2023

•      Merkel Cell Carcinoma Epidemiology Forecast to 2032

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States

Daily Digest Signup

Daily business and market business news, business management tips, market research insights, and more.


Smart public opinion research for everyone.

Generated by Feedzy
%d bloggers like this: